title: Effect of long-term angiotensin-converting enzyme inhibitor therapy on arterial oxygen saturation in patients with mild to moderate heart failure.
abstract: OBJECTIVE
  To evaluate the effects of angiotensin-converting enzyme (ACE) inhibition on continuous pulse oximetry recordings of arterial oxygen saturation (SpO2).
  
  
  METHODS
  Open-label study.
  
  
  METHODS
  Cardiology clinics at two large teaching hospitals.
  
  
  METHODS
  Eight patients with New York Heart Association Functional Class (NYHA FC) II-III heart failure.
  
  
  METHODS
  Patients were studied after an ACE inhibitor washout (baseline, B), and after 3 months following resumption of therapy (ACE).
  
  
  RESULTS
  Monitoring times for B and ACEI were approximately 22 hours. Reduction trends were observed for number (190 +/- 170 vs 125 +/- 67 B vs ACEI), magnitude (8.2 +/- 1.4% vs 7.5 +/- 1.8%), and duration (2.45 +/- 2.8 vs 1.35 +/- 0.8 min) of desaturations/monitoring period, and for nadir SpO2/desaturation (88.1 +/- 1.5% vs 89.9 +/- 3.3%). The B desaturation index [(cumulative desaturation time/monitoring period time) x 100, a measure of hypoxic stress or burden] decreased from 19.4 +/- 8.1% to 11.9 +/- 8.1% at ACEI (p = 0.024).
  
  
  CONCLUSIONS
  Long-term ACE inhibitor therapy improves the profile of SpO2 values over time in patients with NYHA FC II-III heart failure.
authors.affiliation: Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy and Science, PA 19104.
authors.forename: E J
authors.initials: EJ
authors.lastname: Stanek
authors.forename: A R
authors.initials: AR
authors.lastname: Nara
authors.forename: K P
authors.initials: KP
authors.lastname: Strohl
authors.forename: R N
authors.initials: RN
authors.lastname: Nair
authors.forename: M J
authors.initials: MJ
authors.lastname: Decker
authors.forename: M A
authors.initials: MA
authors.lastname: Munger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D010092:Oximetry; D010100:Oxygen / Q000097:blood*; D010101:Oxygen Consumption; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D002216:Captopril; D010100:Oxygen